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Abstract
Background: Though gout is more prevalent in men than women, it remains unclear whether gender influences
risk factors for incident gout. We aimed to systematically review all cohort studies examining risk factors for the
development of gout by gender.
Methods: MEDLINE, EMBASE, CINAHL and the Cochrane Library were searched from inception to March 2019. Risk
factors for gout examined were: age, ethnicity, consumption of alcohol, meat, seafood, dairy products, purine-rich
vegetables, coffee and fructose, vitamin C intake, the Dietary Approaches to Stop Hypertension (DASH) diet,
metabolic syndrome, BMI, waist and chest circumference, waist-to-hip ratio, weight change, diabetes mellitus,
dyslipidaemias, renal disease, psoriasis, hypertension, diuretic use and anti-diabetic medication. Cohort studies were
included if examining (at least) one of these risk factors for gout in either gender in the general population or
primary care. Sample characteristics from included articles and their reported risk estimates were described using
narrative synthesis.
Results: Thirty-three articles were included, 20 (60.6%)directly compared risk factors by gender, 10 (30.3%) used
men-only samples, 3 (9.1%) used women-only samples. Articles comparing risk across genders found similar
increases in most risk factors. However, in men, metabolic syndrome (Hazard Ratio (95% CI) 1.37(1.20–1.58))
presented a risk of incident gout compared to none in women (> 50 years 1.15(0.85–1.54); ≤50 years 1.29(0.76–2.17)).
Compared to men, women showed greater associated risk with higher consumption of fish and shellfish (HR (95% CI)
Men: 1.02 (0.86–1.22); Women 1.36 (1.12–1.65)).
Conclusions: Risk factors for developing gout did not typically differ between genders and therefore similar
preventative advice can be provided. Exceptions were metabolic syndrome in men and excessive seafood
consumption in women, but these singular articles need further examination and in general more research into the risk
factors for gout which includes women is required.
Keywords: Gender, Gout, Risk factors, Systematic review
Introduction
Gout is the most common inflammatory arthritis, with
an increasing prevalence and incidence in recent decades
[1]. Despite this, the management of gout remains
suboptimal and therefore identifying populations at risk
of developing gout, especially those in primary care
where the majority of gout is managed, is important.
Gout is more common in men than women, with only
5.1% of the US gout population being female [2, 3]. This
has typically resulted in the examination of risk factors
for gout focusing on male samples. However, aspects of
gout aetiology in men and women, and therefore poten-
tial risk factors vary between the genders. Gout typically
presents later in women than men, becoming more
prevalent after the menopause. Men more frequently re-
port excessive consumption of foods known to increase
risk of gout [4]. In contrast, women with gout are more
likely than men to have comorbid arterial hypertension
or renal insufficiency, or be overweight or obese [4].
A greater understanding of the differences and
similarities regarding risk and protective factors for
gout between men and women may be an important
factor in developing disease prevention strategies. The
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aim of this systematic review was to compare the
magnitude of risk conferred by predisposing and pro-
tective factors for gout between men and women.
Methods
Literature search
Four electronic bibliographic databases were systematic-
ally searched for articles (MEDLINE, EMBASE, CINAHL
and the Cochrane Library) from their inception to March
2019. MeSH terms (or their database-specific equivalent)
for exposures and outcomes were searched, and exploded
if subcategories were relevant. Free-text phrases were also
used across all databases and no search limits were ap-
plied to the database results.
Eligibility criteria
Articles were included if participants were aged ≥18
years, a prospective or retrospective cohort study design
was used to examine a risk or protective factor for gout
(Table 1) and the outcome was gender-specific gout inci-
dence in a general or primary care population. There
were no language restrictions for inclusion; however, if
translational facilities for an article were unavailable then
it would be excluded.
Screening process
After duplicates had been removed from the initial
search, the titles and abstracts of all of the remaining ar-
ticles were screened by two reviewers. Three assessors
then independently reviewed the full text of the
remaining articles to decide on inclusion. Any disagree-
ments regarding article inclusion were subsequently
arbitrated over by a fourth reviewer.
Data extraction, quality assessment and analysis
Methodological quality of all eligible articles was
assessed independently by two assessors using the
Newcastle-Ottawa Scale (NOS) cohort studies assess-
ment [5]. Disagreement was resolved by consensus
discussion between reviewers. Data were extracted from
all eligible articles by a single author, with half independ-
ently checked by a second assessor. Narrative synthesis
was subsequently conducted, describing the characteris-
tics of each study, along with the risk or protective fac-
tors examined and the risk of developing gout for each.
Results
Literature search
From 54,003 articles identified by the literature search,
35,007 duplicates were removed. The titles and abstracts
of the remaining 18,996 articles were screened, after
which 116 articles remained. After full-text review of
these, 83 articles were excluded leaving 33 articles fulfill-
ing inclusion criteria (Fig. 1).
Twenty-two articles were from the USA, four from
Taiwan, two from the UK and one each from
Australia, Canada, China, Singapore and New Zealand
(Table 2). Thirteen articles (39.4%) examined the inci-
dence of gout in only one gender (Men = 10,
Women = 3), the remaining 20 articles (60.6%) com-
pared both genders. Age as a risk factor was exam-
ined in four articles [6–9], ethnicity in two [10, 11],
dietary risk factors in 16 articles [6–9, 12–23], comor-
bidities and metabolic disorders in 13 [6–9, 24–32]
and medication use in seven [6, 26–28, 33–35].
Quality assessment
The results of the NOS quality appraisal of the included
articles can be found in Additional file 1: Table S1.
Nineteen (57.6%) of the 33 articles used a specific
group of participants in their studies (the Health
Professionals Follow-Up Study and the Nurse’s Health
Study [12, 15, 16, 18, 19, 22, 24, 30], student cohorts
[10, 36], Atherosclerosis Risk in Communities Study
(ARIC) [27, 28, 33], Third Harvard Growth Study
cohort [37], healthy, male runners [13] and hotel
managers and their associates [20]), which are un-
likely to represent the general population. All but one
Table 1 Exposures included in the systematic review
Non-modifiable Diet and Lifestyle Comorbidities Medications
Age Meat Metabolic syndrome Diuretics*
Ethnicity Seafood Obesity/BMI* Anti-diabetic
Purine-rich vegetables Weight change
Low-fat dairy products Hypertension*
Coffee Diabetes mellitus
Fructose Hyperlipidaemia
Vitamin C Renal disease
Alcohol Psoriasis & Psoriatic arthritis
DASH diet
AII = angiotensin II, ACE = angiotensin converting enzyme, BMI = body mass index
* = Discussed in separate article as available for meta-analysis (ref)
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article recruited exposed and non-exposed partici-
pants from the same cohort [10]. Hochberg et al. [10]
used two cohorts of medical students from different
medical schools; the cohort from Johns Hopkins
University School of Medicine was entirely Caucasian
and the cohort from Meharry Medical College was
entirely African-American. The focus of this article
was ethnicity and risk of developing gout; participants
of different ethnicities came from separate cohorts.
Twenty-one (63.6%) articles scored one of the best re-
sponse options (secure record or structured interview)
for ascertainment of exposure [6–9, 11, 21–23, 26–
38]. Ten ascertained exposure status by self-report
[12–19, 24, 39]. Twenty-four (72.7%) specifically
mentioned that participants with prevalent gout were
excluded at the beginning of the study [6–9, 11–16,
18, 19, 22, 24, 27, 30–35, 38].
Two (6.1%) articles provided only unadjusted risk
estimates [20, 26]. Prior et al. [9] provided adjusted risks
for some, but not all, of the exposures included. All
other articles provided results with adjustment for at
least two confounding factors. Twenty-one (63.6%) arti-
cles scored highly (using ACR classification criteria,
ICD9 codes or practitioner diagnosis) for their method
Fig. 1 Flow diagram of the number of articles at each stage of the systematic review
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of gout diagnosis; however, there was no uniform
method used across all studies [6–10, 12, 14–20, 24, 26,
36]. Out of these articles, eight (38.1%) diagnosed gout
using the American College of Rheumatology prelimin-
ary criteria (1977) for gout diagnosis [40]; using this
method a minimum of six out of 11 was needed to be
considered as having gout [12, 14–19, 24]. One (3.0%)
article diagnosed gout based on a clinical impression by
a GP [26]. Hochberg et al. [10] diagnosed gout using
self-report in combination with either a history of mono-
sodium urate crystals in synovial fluid, documented to-
phus or treatment with colchicine, allopurinol or
probenecid. Roubenoff et al. [36] diagnosed gout by
medical chart review after the participant had self-
reported gout. Tofler and Woodings [20] diagnosed gout
based on prescription of un-specified anti-gout medica-
tions by the participant’s own doctor. Ten (30.3%) arti-
cles used record-linkage to diagnose gout [6–9, 23, 31,
32, 35]. Twelve (36.4%) articles diagnosed gout by par-
ticipant self-report [11, 13, 21, 22, 27–30, 33, 37–39].
Two (6.1%) articles found the female portion of their
cohorts too small to reach any conclusion, resulting in a
focus on male patients with gout [26, 37]. Both articles
provided risk estimates for the whole cohort, but when
stratified by gender, could only quantify risk in men be-
cause there were insufficient female cases. Twenty-nine
(89%) articles provided a description of those lost to
follow-up [6–22, 24, 27–33, 35, 36, 38, 39]. The majority
of these were retrospective cohort studies and drew their
study sample from a larger cohort and justified why par-
ticipants from the larger cohort were excluded from
their study. One (3.0%) article lost 45% before their final
follow-up, but did not provide a final loss to follow-up
fig. [37]. Three articles did not describe loss to follow-up
[23, 26, 34].
Narrative synthesis
Age
Four articles examined the risk of developing gout asso-
ciated with age [6–8, 38]. A study from the US reported
a similar increased risk of developing gout associated
with a five-year increase in age in men & women (ad-
justed relative risk (RR) (95% confidence interval (95%
CI); Men:1.14(1.03–1.26; Women: 1.24 (1.08–1.43)) [6].
Two studies from Taiwan found similar 2–3% increases
in risk of gout with every one-year increase in age in
men (adjusted Hazard Ratio (HR) 1.03 (95% CI 1.02–
1.03) [7]; 1.02 (1.02–1.03) [8]); however, for women, one
reported a 5% increased risk in women (1.05 (1.04–1.06)
and the other compared risk of gout in women stratified
by age (> 50 years:1.03 per one-year increase (95% CI
1.01–1.05); ≤50 years: 1.08 (1.05–1.11)) [7, 8]. A study
from New Zealand [9] found a small increased risk of
gout with a one-year increase in age in men (adjusted
odds ratio (OR) (95% CI) 1.05(1.02–1.07)), but did not
include women (Additional file 1: Table S2).
Ethnicity
Two articles from the US [10, 11] examined the associ-
ation between ethnicity and the risk of incident gout,
with one focussing on men [10] and the other compar-
ing genders [11]. In the study which examined [10] two
cohorts of male, former medical students the unadjusted
risk of developing gout in African-Americans compared
to Caucasians was initially significantly greater (RR
(95%) 1.69(1.02–2.80)), but was attenuated after adjust-
ment for hypertension and BMI (RR (95% CI) 1.30(0.77–
2.19)). A population-based study found a similarly in-
creased risk of gout in African-Americans compared to
Caucasians in men and women (adjusted RR (95% CI)
men: 1.49 (1.11–2.00), women: 1.69 (1.29–2.22)) [11]
(Additional file 1: Table S3).
Dietary factors
Fifteen articles examined the risk of dietary factors on
gout, with the majority of these examining the risk asso-
ciated with meat, seafood, dairy consumption and a
DASH (Dietary Approaches to Stop Hypertension) diet
in male-only studies and therefore comparative results
are presently unavailable. The results of the single-
gender papers which investigated the above risks are
available to view in Additional file 1: Table S4. In a
Singapore population, Teng et al. examined the role of
different sources and quantities of dietary protein con-
sumed on the risk of incident gout in men and women
[21]. They examined risk related to; total protein intake,
soy protein, fish and shellfish, red meat, poultry, eggs,
dairy, soy foods, non-soy legumes, nuts and seeds and
all grain. Though risk or protection from gout was com-
parable across the majority of these protein sources for
men and women, they found that in women, there was
increased risk of gout in those with the highest levels of
consumption of fish and shellfish (HR 1.36 (1.12–1.65))
compared to the lowest levels of consumption and a
protective effect in those with the highest consumption
of non-soy legumes (HR 0.77 (0.64–0.94)) compared to
the lowest consumption. There was no significant
difference for men for either of these factors.
The HPFS study in men and Nurses’ Health Study in
women examined coffee consumption as a potential risk
factor for gout [14, 15]. Risk of incident gout was halved
in women consuming ≥4 cups of coffee per day
(adjusted RR (95% CI) 0.43(0.30–0.61)) and lower in
men consuming 4–5 cups (0.60 (0.41–0.87)) or ≥ 6 cups
(0.41 (0.19–0.88)) per day compared to non-drinkers of
coffee. In the Nurses’ Health Study, risk of incident gout
was lower in women consuming at least 1 cup of decaf-
feinated coffee per day compared with those drinking no
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cups (adjusted RR 0.77(0.63, 0.95)). In the HPFS, gout
incidence was lower in men who drank decaffeinated
coffee, but only less than or equal to 4 a day (≥4 cups
per day; 0.73 (0.46–1.17)). Neither study found an asso-
ciation between tea consumption and incident gout
(Additional file 1: Table S5).
Two articles examined fructose and sugars and their
association with incident gout in the HPFS and Nurses’
Health Study [16, 17]. There was a relationship between
the highest consumption of sugar-sweetened cola and
other sweetened soft drinks and an increased risk of in-
cident gout in men, but not for diet soft drinks. The
same pattern was seen for women in the Nurses’ Health
Study [17]. Both articles examined fruit juices, reporting
that high levels of consumption were associated with
incident gout in men and women. Furthermore, they
reported that increasing consumption of free (as a
monosaccharide) and total fructose (calculated as free
fructose plus half of sucrose) are risk factors for gout in
both men and women (Additional file 1: Table S6).
One study examined the potential protective effects of
total and supplemental vitamin C intake against the risk
of developing gout in men [18], but none examined the
risk in women. (Additional file 1: Table S7).
Seven articles examined the association between alcohol
consumption and incident gout [6, 8, 9, 13, 19, 20, 23],
with three directly comparing men and women [6, 8].
Chen et al. [8] examined the overall risk in men and
women (women < 50 years of age and women ≥50 years of
age) who drank alcohol (including abstainers) and devel-
oped gout compared to those who never drink and found
no statistically significant risk. Bhole et al. [6] reported
that alcohol presented a similar increased risk of
developing gout in men and women, (risk in heavy
drinkers (≥7 oz. per week) (Men: RR (95% CI) 2.21(1.56–
3.14); Women 3.10 (1.69–5.69)). Tu et al. [23] examined
the risk of alcohol-related disease in men and women and
the incidence of gout. Their findings supported the
importance of alcohol intake and the development of
gout, but this was irrespective of gender (men HR
1.81 (1.64–1.99); women HR 2.48 (1.97–3.13)). The
remaining four articles all reported a greater risk of
men developing gout in alcohol drinkers compared to
those who do not drink alcohol [9, 13, 19, 20]. There
were no articles examining the risk of gout in
women-only samples. (Additional file 1: Table S8).
Comorbidities
Metabolic syndrome
Only one study [8] examined the role of metabolic syn-
drome (defined as three or more of the following; central
obesity, hypertriglyceridaemia, low high-density lipopro-
teins, hypertension and hyperglycaemia) as a risk factor
for gout in men and women. Though there was an initial
association between metabolic syndrome and incident
gout for both genders, this was only retained in men
after adjustment, (Men: HR (95% CI) 1.37 (1.20–1.58);
Women > 50 years 1.15 (0.85–1.54); Women ≤50 years
1.29 (0.76–2.17)) (Additional file 1: Table S9).
Body mass index
Ten articles considered the role of BMI on incident gout
within the context of a specific gender, with three com-
paring men and women [6–8], six including only men
[9, 10, 13, 24, 36, 37] and one including only women
[38]. Chen et al. [7] reported a significant risk of
developing gout for those with a BMI of ≥27 kg/m2 in
both genders, although it was greater in women (ad-
justed RR (95% CI) 1.30(1.15–1.47) in men, 2.15 (1.67–
2.76) in women). When stratifying women by meno-
pausal status the risk remained significant for both, but
was more prominent in pre-menopausal women (Pre-
menopause: RR (95% CI) 2.50(1.38–4.52); Post-
menopause 1.90 (1.44–2.51)). In their 2013 article, Chen
et al. [8] found the risk of incident gout conveyed by a
BMI of ≥27 kg/m2 to be greater in women aged > 50
years (1.97 (1.48–2.62)) than men (1.30 (1.11–1.53)),
while the risk for women ≤50 years was not statistically
significant (1.63 (0.93–2.86)). Bhole et al. [6] reported
that obese men and women (those with BMI of ≥30 kg/
m2) were over two half times more likely to develop gout
(Men: RR (95% CI) 2.90(1.89–4.44); Women 2.74 (1.65–
4.58)); however, only men were at risk (1.76 (1.22–2.54))
when categorised as overweight (25–29.9 kg/m2). Must
et al. [37] found no association between obesity, defined
as a BMI between 22 and 25 in boys and 22–24 in girls,
during adolescence (13 to 18 years of age) and the
development of gout later in life. Choi et al. [24] and
Williams et al. [13] reported risk of incident gout in
men increased in line with increasing BMI; however,
Hochberg et al. and Roubenoff et al. both found no asso-
ciation [10, 36]. Maynard et al. [38] studied only females,
and found that obese women had double the risk of
developing gout (RR 2.37 (1.53–3.68)) than non-obese
women (Additional file 1: Table S10).
Waist and chest circumference
Two articles examined risk associated with waist and
chest circumference. Chen et al. [8] defined central
obesity as waist circumference greater than 90 cm in
men and 80 cm in women, reporting adjusted hazard
ratios (95% CI) of 1.30(1.13–1.50) in men and 1.39
(1.01–1.92) in women aged over fifty years compared to
those without central obesity. In women fifty years of
age or younger the risk was not significant (HR (95% CI)
1.45 (0.91–2.30)). In an all-male cohort, Williams [13]
found no association between a per centimetre increase
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in waist or chest circumference and risk of gout after
adjustment (Additional file 1: Table S11).
Waist-to-hip ratio
Two articles examined risk associated with waist-to-hip
ratio (WHR). Choi et al. [24] and Maynard et al. [38]
conducted similar studies into WHR and the risk of
developing gout, but with all-male and all-female co-
horts respectively. Choi et al. [24] reported an associ-
ation between WHR and the development of gout in
men in their highest two categories (WHR 0.95–0.97, ad-
justed RR (95% CI) 1.35(1.01–1.79), WHR 0.98–1.39,
1.82(1.39–2.39)). Maynard et al. [38] also reported in-
creased risk in women with a WHR > 0.968 compared to
those with a WHR < 0.900 (adjusted RR (95% CI)
2.78(1.65–4.70)) (Additional file 1: Table S12).
Weight change
Three articles, [24, 36, 38] reported risks of gout associ-
ated with weight change, with two [24, 36] using all-
male cohorts, and one [38] using an all-female cohort.
In men, an increase in BMI between entry into the
study’s cohort and age 35 years of > 1.88 doubled the risk
of gout (RR 2.07 (95% CI not reported)) and an increase
in weight of ≥2.7 kg had a similar risk (RR 1.87), adjusted
for age and hypertension [36]. Choi et al. [24] studied
weight change from age 21 years and from cohort entry
at baseline for men. Weight loss from either reduced risk
of gout, though this was only statistically significant for
the loss of >10lbs from cohort entry (adjusted RR (95%
CI) 0.61 (0.40–0.92)). Increases in weight from age 21
years showed an increased risk of gout; in the adjusted
model this was only significant with weight gain of
20-29lbs and > 30lbs (RR (95% CI) 20-29lbs: 1.39
(1.02–1.90), >30lbs: 1.99 (1.49–2.66)). Though the risk
associated with weight change from baseline varied
across the categories, the greatest weight loss (−10lbs
or more) was protective (0.61 (0.40–0.92) and greatest
weight gain (+30lbs or more) increased the risk of
gout (1.72(1.02–2.91)).
In women, Maynard et al. [38] also found the greatest
weight gain change (≥16.3 kg) from 21 to 25 years of age
doubled the adjusted risk for incident gout (2.05 (1.06–
3.96) (Additional file 1: Table S13).
Diabetes mellitus
Four articles examined the risk of developing gout
associated with diabetes mellitus. These studies were
undertaken in population-based samples, stratified by
men and women [6–8, 34]. Bhole et al. [6] reported no
association between a 10 mg/dl increase in blood glucose
levels and risk of incident gout in either gender. Chen et
al. [7] reported that diabetes mellitus was not associated
with an increased risk of gout in men or women, or
either of their stratifications of women by menopausal
status. Chen et al. [8] reported no association of gout
with hyperglycaemia. (Additional file 1: Table S14).
Finally, the study by Wijnands et al., the most recent
and largest of the four included articles, found that
individuals with type 2 diabetes were initially at
increased risk of gout, but after adjustment the risk
disappeared in women (HR 1.01; 95% CI 0.92–1.11)
and reversed in men (HR 0.61;95% CI 0.58–0.66) [34]
(Additional file 1: Table S20).
Dyslipidaemias
Four articles examined risk associated with dyslipidae-
mias. Prior et al. [9] reported that elevations of both
serum cholesterol and triglycerides of 1 mmol/l signifi-
cantly increased the risk of gout in men. Bhole et al. [6],
however, found no association between gout and an in-
crease in blood cholesterol of 10 mg/d in either gender.
Chen et al. [7] explored the role of hyperlipidaemia, de-
fined as blood cholesterol levels ≥240 mg/dl or triglycer-
ide levels ≥200 mg/dl, in the predisposition to gout.
They reported that it was only significant in women (HR
(95% CI) 1.70(1.32–2.19)), and after stratification by
menopausal status it remained significant in only post-
menopausal women (HR (95% CI) 1.59(1.20–2.09)).
Hypertriglyceridaemia, defined as blood triglycerides
levels greater than 150mg/dl, were significantly associ-
ated with gout in men (HR (95% CI) 1.39(1.21–1.60))
and women over fifty years of age (HR (95% CI)
1.37(1.02–1.83)) in the article by Chen et al. [8]
(Additional file 1: Table S15).
Renal disease
In a men only dataset, Choi et al. [24] reported an in-
creased risk of gout associated with chronic renal failure
(unadjusted RR (95% CI) 3.61(1.60–8.14)); this risk in-
creased when looking at a subset of those with chronic
renal failure who had had no exposure to diuretics (RR
(95% CI) 4.60(1.88–11.25)). When Tan et al. [32]
examined specific levels of kidney function (eGFR) and
3-year cumulative incidence of gout in both men and
women, they found that risk in men was significantly
higher across all levels of kidney function (eGFR> 90ml/
min per 1.73 m2, 60–89, 45–59, 30–44, 15–29) than
women, except for the chronic dialysis group. However,
though Chen et al. [8] and Wang et al. [31] both found
an association between renal insufficiency and chronic
kidney disease respectively on the risk of gout, there was
little difference in risk between the genders. (Additional
file 1: Table S16).
Hypertension
Ten articles explored hypertension as a risk factor for
gout [6–10, 24, 26, 28, 29, 36], of which five articles
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compared the associations between hypertension and in-
cidence gout in men and women. Three [6, 25, 29]
found increased incidence in both genders, one [8]
found the incidence of gout in hypertensive patients to
only be raised in men and another found the risk of gout
was only increased in female hypertensive patients [28].
Five further articles examined risk in male only samples.
All found increased incidence of gout, though only two
adjusted for covariates [9, 10, 24, 26, 36]. There were no
articles examining the risk of hypertension in women-
only samples (Additional file 1: Table S17).
Psoriasis/psoriatic arthritis
One article examined the association of psoriasis and
psoriatic arthritis with incident gout [30]. This article ex-
amined these associations on both men and women, but
using two separate datasets for either gender, the HFPS
and NHS for men and women respectively. Though the
risk of gout was increased in men and women with psor-
iasis and psoriatic arthritis, risk was greater in men with
confirmed psoriasis then women (HR (95% CI) Men:
2.72 (1.75, 4.25); Women 1.40 (0.90, 2.19)) (Additional
file 1: Table S19).
Diuretics
Three articles examined diuretic use against no diuretic
use. One compared genders [6], and two used male-only
samples [24, 26]. All reported that there was a statisti-
cally significant association between diuretic use and in-
cident gout, even after adjustment. Only Bhole et al. [6]
examined the differences in risk between genders,
reporting a similar risk in both (Men: RR (95% CI)
3.41(2.38–4.89); Women: (2.39 (1.53–3.74)). Choi et al.
and Grodzicki et al. used male-only samples [24, 26], the
former reporting an increased risk of 1.77 (1.42–2.20)
after adjustment, the latter reporting a crude risk esti-
mate of 6.25 (2.4–16.70) (Additional file 1: Table S18).
Pioglitazone
A study by Niu et al. (2017) [35] examined the associ-
ation of pioglitazone on incident gout in men and
women with Diabetes Mellitus, reporting that the inci-
dence of gout was significantly lower in pioglitazone
users than in non-pioglitazone users [adjusted hazard
ratio (aHR) 0.81 (95% CI 0.78, 0.85)]. The HR for the
incidence of gout was lower in both male [aHR 0.80
(95% CI 0.75, 0.85)] and female [aHR 0.83 (95% CI 0.78,
0.88)] pioglitazone users than in non-pioglitazone users
(Additional file 1: Table S20).
Discussion
This systematic review identified all cohort studies
which examined well-established risk and protective
factors for gout, specifically examining differences in risk
between the genders. We found that the risk of develop-
ing gout was influenced by many demographic, dietary,
comorbid and pharmacological risk factors, and for
many of these risk factors, risk was similar for men and
women. However, there were exceptions such as meta-
bolic syndrome, which conferred a greater risk in men
and increased intake of fish and shellfish, which has a
greater association with risk of gout in women.
There are results which suggest different risks be-
tween genders, but from which it is difficult to come
to conclusions. For example, for diuretic use, the
magnitude of risk estimates suggested a greater risk
in men, but there was significant overlap of 95% CI
between the genders precluding firm conclusions [6].
Aspects of diet (consumption of meat, fish, purine-
rich vegetables and vitamin C etc) were the most fre-
quently examined of the risk factors, but due to the
many potential components of diet, the variety of
ways in which consumptions was quantified in each
article and the predominate use of male-only datasets,
our ability to compare gender stratified datasets was
extremely limited. There was only one study to con-
sider dietary risk of gout in men and women, Teng et
al. examined a multitude of sources of protein in a
large sample from Singapore, finding fish and shellfish
to increase the risk of gout in women, but not men.
As this was only one study we are cautious with our
inferences, but further research into this area would
not only provide a useful illumination for the female
population regarding gout; comparative studies inves-
tigating male and female association between diet and
risk of gout could provide useful insights into the
dietary component of gout’s aetiology.
Though also only investigated in a single article, the
difference in risk associated with metabolic syndrome
between the genders seems plausible, due to the large
sample size and relatively even proportion of men
and women. Metabolic syndrome was reported to be
associated with gout in men, but not women. This
could be due to the fact that, despite a large sample
size the number of cases of gout in women remained
low (202 in those older than 50, 88 in those equal to
or younger than 50). More research in this area
would be of benefit.
The articles that examined age, renal insufficiency,
fructose consumption and hypertension reported in-
creases in risk that were statistically significant and of
a similar magnitude in both, men and women. Chen
et al. [7, 8] highlight the importance of age when
considering gender, with older women (> 50 years) be-
ing at increased risk. Though this risk factor is non-
modifiable, it remains important to highlight that
older patients may need greater monitoring, especially
in women due to the apparent risk increases post-
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menopause. With regard to comorbidities, it is clear
that hypertension is associated with increased risk of
developing gout, but the strength of this association
is not agreed upon, with the reported risk ranging by
an order of magnitude from 33 to 400% [25, 26]. The
presence of psoriasis also increases the risk of gout
and may have a greater role in men than women.
However, the article by Merola et al. demonstrating
this used data from two separate male and female
datasets and therefore a direct comparisons is limited.
Ethnicity and diabetes mellitus showed no definitive
association with altered risk of gout between either
genders. Only one study considered the role of gender in
the risk of developing gout in different ethnic groups.
Though relative risk was 20% greater in men than
women, again, overlapping confidence intervals
suggested little actual difference between the genders.
Few studies reported protective factors for gout, espe-
cially comparing this across genders. A single study by
Teng et al., reported that high consumption of non-soy
legumes was protective in women, compared to those
with the lowest consumption, although this protection
was not demonstrated in men.
Strengths and limitations
A strength of this systematic review was the lack of re-
strictions placed on the search. All widely established
risk and protective factors were included, allowing a
comprehensive comparison of factors associated with
gout. Furthermore, there were no restrictions on year of
publication as databases were searched from their incep-
tion and publications in all languages were included and
translated and only cohort study designs were included.
Our research does have limitations due to several arti-
cles using specific samples (e.g. health professionals),
thereby possible reducing generalisability. The included
studies used a range of different data collection methods,
including self-report, measurement and record-linkage,
potentially introducing heterogeneity. Related to this
point, we were unable to conduct a meta-analysis due to
the aforementioned heterogeneity.
Conclusion
This systematic review identified several risk factors for
the development of gout, with the degree of risk be-
tween the genders predominantly being consistent and
therefore meaning similar preventative advice can be
provided. However, metabolic disorder and an excess
consumption of fish and shellfish may presents a greater
risk of developing gout in men and women respectively.
Far more research into the risk factors for gout which
includes women is required to be confident that no fur-
ther differences exist.
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